Eva Pokorna

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Allogeneic Hematopoietic Stem Cell Transplantation

Acute Lymphoblastic Leukemia

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Alexandra Dolnikova, Dmitry Kazantsev, Magdalena Klanova, Eva Pokorna, Dana Sovilj, Cristina Daniela Kelemen, Liliana Tuskova, Eva Hoferkova, Marek Mraz, Karel Helman, Nikola Curik, Katerina Machova Polakova, Ladislav Andera, Marek Trneny, Pavel Klener
Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status. Blood advances 8 (13) (2024)
Alexandra Dolnikova, Dmitry Kazantsev, Magdalena Klanova, Eva Pokorna, Dana Sovilj, Cristina Daniela Kelemen, Liliana Tuskova, Eva Hoferkova, Marek Mraz, Karel Helman, Nikola Curik, Katerina Machova Polakova, Ladislav Andera, Marek Trneny, Pavel Klener
Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status. Blood advances 8 (13) (2024)
Alexandra Dolnikova, Dmitry Kazantsev, Magdalena Klanova, Eva Pokorna, Dana Sovilj, Cristina Daniela Kelemen, Liliana Tuskova, Eva Hoferkova, Marek Mraz, Karel Helman, Nikola Curik, Katerina Machova Polakova, Ladislav Andera, Marek Trneny, Pavel Klener
Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status. Blood advances 8 (13) (2024)
Alexandra Dolnikova, Dmitry Kazantsev, Magdalena Klanova, Eva Pokorna, Dana Sovilj, Cristina Daniela Kelemen, Liliana Tuskova, Eva Hoferkova, Marek Mraz, Karel Helman, Nikola Curik, Katerina Machova Polakova, Ladislav Anděra, Marek Trněný, Pavel Klener
Blockage of BCL-XL overcomes venetoclax resistance across BCL2-positive lymphoid malignancies irrespective of BIM status. Blood advances (2024)
Alexandra Dolnikova, Dmitry Kazantsev, Magdalena Klanova, Eva Pokorna, Dana Sovilj, Cristina Daniela Kelemen, Liliana Tuskova, Eva Hoferkova, Marek Mraz, Karel Helman, Nikola Curik, Katerina Machova Polakova, Ladislav Andera, Marek Trneny, Pavel Klener
Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status. Blood advances 8 (13) (2024)